Jason M. Broderick is a journalist at various esteemed publications, including Diagnostic Imaging® and Cancer Network. He specializes in medicine and healthcare, focusing on critical topics such as oncology, immunotherapy, and pancreatic cancer research, while also covering hematology, endocrinology, and palliative care. Jason's work has been featured in multiple outlets, including CURE Media Group and Urology Times, showcasing his commitment to advancing knowledge in medical specialties and alternative medicine.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Jason M. Broderick's coverage predominantly revolves around healthcare and pharmaceutical topics, with a particular focus on scientific research and data-driven insights in the medical field. His articles often cite specific data, indicating an emphasis on evidence-based reporting.
Given his engagement with scientific findings and healthcare advancements, he is likely to be interested in pitches that offer access to new clinical studies, innovative medical technologies, or expert commentary from professionals involved in cutting-edge research within the specified medical domains. Pitches centered around breakthroughs related to bladder cancer treatment modalities, biomarker discoveries, urine testing innovations, or cancer diagnosis methodologies could align well with his coverage interests.
As Jason’s geographic focus is not specified but the content of his articles indicates a broad international perspective focused on developments across various regions without restriction to any specific location.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Jason M. Broderick
FDA authorized lutetium Lu 177 dotatate for adult SSTR-positive GEP-NETs, positioning PRRT as a theranostic extension for foregut, midgut, and hindgut neuroendocrine primaries. ERASMUS efficacy in 360 GEP-NET patients showed 17% ORR (3 complete responses) and median duration of response 35 months, with FDA counting only prospectively assessed responders.
By: Jason M. Broderick
Overall survival improved with tam-peli versus topotecan (13.3 vs 9.4 months; HR 0.46), with consistent benefit across key subgroups including brain/liver metastases and chemotherapy-free interval. Progression metrics strongly favored tam-peli (PFS 7.4 vs 2.8 months; HR 0.29) alongside higher ORR (59.1% vs 9.7%) and disease control (91.1% vs 50.9%).
By: Jason M. Broderick
Fast Track designation supports expedited development of LYT-200 plus an HMA in R/R HR-MDS following prior HMA relapse or refractoriness, addressing a setting where HMA rechallenge responses are typically <5%. Phase 1b signals showed ORR 45.5% with LYT-200 12 mg/kg plus azacitidine/decitabine, including CR 27.3%, PR 9.1%, and marrow CR 9.1%, enabling 18% transplant conversion.
By: Jason M. Broderick
FDA recommended a new survival-confirmatory trial prior to BLA submission, despite statistically significant ORR and PFS benefits for tovecimig plus paclitaxel in COMPANION-002. Intention-to-treat OS was neutral (HR, 1.05), but 54% crossover from control led to 85% of participants ultimately receiving tovecimig, complicating OS interpretability.
By: Jason M. Broderick
FDA approval covers previously treated advanced CCA with FGFR2 fusions/rearrangements, adding another targeted option beyond pemigatinib and futibatinib in the post–first-line setting.
By: Jonah Feldman, Jason M. Broderick
Approval is supported by LITESPARK-011 showing superior RECIST v1.1 PFS for belzutifan/lenvatinib versus cabozantinib after PD-1/PD-L1 progression (HR 0.74; 1-sided P=.00095). Objective responses were more frequent and deeper with the combination, including more complete responses and longer response durability versus cabozantinib in interim reporting.
By: Jason M. Broderick
Sequential cohorts escalate alisertib by 10 mg BID if ≤3 protocol-defined safety events occur in cycle 1, capping at 70 mg BID, with primary focus on treatment-emergent AEs/SAEs. Earlier randomized phase 2 data showed improved PFS after relapse-definition correction (HR 0.71; P=.038) and ORR 22% with alisertib-paclitaxel, versus ORR 18% for paclitaxel alone.
By: Jason M. Broderick
FDA indicated phase 2 IDeate‑Lung01 data and supporting evidence did not satisfy accelerated approval standards, prompting voluntary withdrawal despite Priority Review and an October 2026 action date. Efficacy at 12 mg/kg q3w (n=137) showed BICR ORR 48.2%, DCR 87.6%, median DOR 5.3 months, PFS 4.9 months, OS 10.3 months.
By: Jason M. Broderick, Jonah Feldman, Sabrina Serani
Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
By: Jason M. Broderick
ESMO 2026 Presidential Symposium II recap: survival benefits reported across phase 3 Krascendo 1, SAFFRON, CLARITY-Gastric01, and HARMONi-GI1 trials.
